Androgenetic Alopecia Research Articles

53289 Clinical and metabolic characteristics of male patients with early-onset androgenetic alopecia: A possible predisposition to metabolic syndrome

53289 Clinical and metabolic characteristics of male patients with early-onset androgenetic alopecia: A possible predisposition to metabolic syndrome

53039 The prevalence of androgenetic alopecia with hormone therapy in transgender men: a systematic review and single-arm meta-analysis

53039 The prevalence of androgenetic alopecia with hormone therapy in transgender men: a systematic review and single-arm meta-analysis

52952 Oral Minoxidil New York Times Coverage: The Impact on Patient Perceptions and Dermatologists’ Approaches to Androgenetic Alopecia

52952 Oral Minoxidil New York Times Coverage: The Impact on Patient Perceptions and Dermatologists’ Approaches to Androgenetic Alopecia

The association between alcohol consumption and the severity of male androgenic alopecia in Chinese participants: A single-center cross-sectional study

The association between alcohol consumption and the severity of male androgenic alopecia in Chinese participants: A single-center cross-sectional study

The History and Current Status of Platelet-Rich Plasma Therapy in Dermatology.

Since the 1800s, platelet-rich plasma (PRP) has been used as a treatment for a wide range of medical conditions with a concomitant effect of tending to reduce the need for some invasive procedures. The aim of this narrative review was to concisely document the history and current usage of PRP specifically in the field of dermatology. Four databases (PubMed, Google Scholar, CINAHL, and Web of Science) were searched for primary articles written in English that evaluated human subjects and focused on PRP use in dermatology. Initial search terms included "platelet rich plasma,""alopecia,""androgenic alopecia,""dermatology,""PDGF,""aging,""skin rejuvenation,""diabetic ulcers,""venous leg ulcers," "acne,""acne scars,""scars,""hyperpigmentation,""melasma,""hypopigmentation,""vitiligo,"and "PRP."After review, articles were excluded if they were commentaries, editorials, animal studies, review articles, or were unrelated to dermatology. The bibliography of retrieved articles was also searched for relevant articles.The present review results describe the function of PRP from its first usage for thrombocytopenia to its usage for melasma. In this time frame, its use in dermatology has gone through many evolutions from using its healing factors for treating wounds to using it as the treatment for wrinkles, hair loss, scars, ulcers, and skin pigmentation disorders. Its anti-inflammatory and growth factors have been shown to initiate a healing cascade that promotes the growth and regeneration of tissues. It is hoped that this review will help educate patients and physicians about the efficacy of PRP therapy and thereby help avoid unnecessary invasive procedures for certain conditions.

Vorasidenib-Induced Trichomegaly and Hypertrichosis: a New Side Effect in a Patient with Diffuse Astrocytoma.

Vorasidenib, an oral dual inhibitor targeting mutant enzymes isocitrate dehydrogenase 1 and 2, is utilized in the management of diffuse low-grade gliomas. Despite limited documentation of its adverse events, we present the case of a 44-year-old male who exhibited trichomegaly and hypertrichosis of body hair, eyebrows, and eyelashes following one month of vorasidenib treatment. Notably, the patient experienced diffuse hair regrowth on the scalp, including in areas affected by severe androgenetic alopecia. This report holds significance as it highlights a previously unreported side effect, thereby enhancing our understanding of emerging therapies for brain tumors and their associated adverse reactions.

Randomized Clinical Trial to Evaluate the Effect of Probiotic Intake on Androgenic Alopecia.

This study aimed to assess the impact of a combination of probiotic strains of Lactiplantibacillus on the treatment of androgenic alopecia (AGA). To this end, 136 individuals with AGA (62 men and 74 women) aged 18-65 years were enrolled in a double-blind, parallel-group clinical trial. A total of 115 individuals (57 in the probiotic group and 58 in the placebo group) completed this study within a 16-week intervention period. Capillary density, thickness, and length of hair were analyzed before and after the intervention using FotoFinder Trichoscale Pro. In addition, the gut microbiota was assessed by paired-end sequencing on the Illumina MiSeq platform (2 × 300 bp). At the conclusion of the treatment period, a notable decline (p < 0.05) in the number of telogen hairs was evident in the probiotic group while hair thickness decreased in the placebo group (p < 0.05). However, the remaining variables did not exhibit any statistically significant changes. In the probiotic-treated group, individuals aged less than 37.5 years exhibited a reduction in the number and density of telogen hair (p = 0.0693 and p = 0.0669, respectively) and an increase in hair length (p = 0.0871). Furthermore, a notable decline in the number and density of vellus hair (p < 0.05) was observed, and this was accompanied by no change in the hair thickness. The probiotic-treated group exhibited a significantly higher abundance of Lactobacillus (p-adjusted < 0.05, DEseq2 test) and demonstrated a notable reduction in the number and density of telogen hair, and this was accompanied by an increase in the percentage of anagen hair. The probiotic mixture was well tolerated by the participants, with a treatment adherence rate of 90%. In light of this study's limitations, it can be concluded that a mixture of three strains of Lactiplantibacillus promotes the presence of terminal follicles, preventing their gradual miniaturization, which is a characteristic of AGA.

The comparison of metabolic syndrome parameters, trichoscopic and trichoscan characteristics in androgenetic alopecia (AGA) and early-onset androgenetic alopecia (early-onset AGA).

Androgenetic alopecia (AGA), the most common cause of hair loss, is influenced by various risk factors. Metabolic syndrome constitutes a collection of risk factors elevating the risk of cardiovascular disease. The presence of early-onset AGA could serve as an indicator of the emergence of metabolic syndrome, yet to date, no research has examined these parameters in AGA. This is a cross-sectional study comparing two groups; early onset versus normal onset AGA. Forty participants were enlisted and evenly distributed into the two groups. Subsequently, participants underwent examinations utilizing trichoscopy, trichoscan, and laboratory assessments. Apart from waist circumference, BMI, and age of alopecia onset, there were no notable differences concerning sociodemographic and clinical features. In terms of hair growth parameters, the telogen hair rate stands out as the sole indicator exhibiting a significant difference between both groups, while trichoscopy data also revealed varying hair characteristics. Lastly, metabolic parameters namely triglyceride, fasting blood glucose, HbA1c and HDL differ significantly, with the normal onset group demonstrating a higher prevalence of metabolic abnormality. This suggests a potential association between AGA and metabolic syndrome. However, the exact nature of this relationship remains uncertain, necessitating further research with larger samples, specific age groups and diverse study designs.

Efficacy and safety of microneedling radiofrequency in patterned hair loss.

We aimed to assess the improvement of patterned hair loss with microneedling radiofrequency (MNRF) and its adverse effects in patients. An open-label study was conducted to evaluate the efficacy and safety of MNRF for the treatment of androgenetic alopecia. Patients diagnosed with patterned hair loss received three MNRF treatment sessions once monthly. Efficacy was assessed by comparing before and after photographs and trichoscopy. Twenty-four patients were recruited. Excellent improvement in hair growth was observed in 14 patients, fair improvement in seven patients, and no improvement in three patients without significant adverse effects. Slight pain lasting for a day was the most common adverse event following MNRF. Overall, significant improvement was observed in the majority of the patients without significant side effects.

Association of Ferritin and Vitamin-D (Calciferol) Deficiency with Female Pattern Hair Loss

Association of Ferritin and Vitamin-D (Calciferol) Deficiency with Female Pattern Hair Loss

A Study of Prevalence of Metabolic Syndrome in Premenopausal Women With Female Pattern Hair Loss: A Case-Control Study.

Background and objective Female pattern hair loss (FPHL), also known as androgenetic alopecia (AGA), is a condition where the hair follicles of genetically susceptible women gradually shrink and become thinner, leading to hair loss in a particular pattern. Metabolic syndrome (MS) is a collection of conditions that co-occur, increasing the risk of heart disease, stroke, and type 2 diabetes. This study aims to determine the prevalence of MS in premenopausal women in patients with FPHL. Methods and materials We conducted a case-control, hospital-based observational study at our institution for a period of two years, which included 62 patients, with 31 cases (patients with FPHL) and 31 controls (patients without FPHL). Results In some cases, the mean age was 29.81 years, while in controls, it was 28.84 years. The mean waist circumference (WC) in cases was 81.9+/- 11.75 cm, and in controls, it was 72.65+/- 8.86 cm, with a statistically significant p-value of 0.001. In some cases, the mean body mass index (BMI) was 26.28 +/- 4.09 kg/m2, and in controls, it was 24.52 +/- 2.78 kg/m2, with a statistically significant p-value of 0.013. Between cases and controls, there was no significant difference in the homeostatic model assessment of insulin resistance (HOMA-IR), fasting blood glucose (FBG), fasting triglyceride levels, fasting HDL, and fasting insulin levels. Conclusion The study found a significant association between WC and BMI in patients with FPHL in premenopausal women. This highlights the need for early screening and preventive measures for MS in women presenting with FPHL.

The additive value of platelet-rich plasma to topical Minoxidil in the treatment of androgenetic alopecia: A systematic review and meta-analysis.

It still needs to be determined if platelet-rich plasma (PRP) has any added advantage over Minoxidil in treating androgenetic alopecia. We reviewed randomized controlled trials (RCTs) comparing scalp injections of PRP plus Minoxidil vs Minoxidil alone for managing androgenetic alopecia. All RCTs published on Embase, Cochrane Library, and PubMed comparing PRP plus Minoxidil vs. Minoxidil alone were eligible. The literature search was completed on 5 March 2024. The review was registered on PROSPERO (CRD42024509826). Of five included RCTs, three had a high risk of bias, while one had some concerns. A systematic review of the studies showed that all trials reported better outcomes with PRP plus Minoxidil than with Minoxidil alone. Meta-analysis showed that hair density at one month (MD: 11.07 95% CI: 1.20, 20.94 I2 = 0%), three months (MD: 21.81 95% CI: 10.64, 33.00 I2 = 57%) and 5/6 months (MD: 17.80 95% CI: 7.91, 27.69 I2 = 80%) of follow-up was significantly better in the PRP plus Minoxidil vs the Minoxidil alone group. Meta-analysis of adverse events showed that the risk of adverse events was comparable in both groups (OR: 0.55 95% CI: 0.22, 1.36 I2 = 0%). The certainty of evidence on the GRADE assessment was "low to very low." Very low-quality evidence shows that the addition of injectable PRP to topical Minoxidil may improve outcomes in patients with androgenetic alopecia. The addition of PRP was found to improve hair density and patient satisfaction significantly. However, the small number of studies with a high risk of bias and heterogeneity in PRP preparation methods are significant limitations of current evidence. Further studies with larger sample sizes and uniform PRP preparation protocols are needed.

Bioactives in Nutricosmetics: A Focus on Caffeine from Tea to Coffee

Known for its stimulating effects on the nervous and cardiovascular systems, caffeine has proven remarkable versatile properties. It can be used in a wide range of different products, from anti-aging cosmetics to the pharmaceutical treatment of hair loss. Caffeine is known for its antioxidant properties and is commonly found in moisturising creams recommended as anti-aging or anti-cellulite and also for the treatment of different skin disorders, including androgenic alopecia. This bioactive is also described to be able to enhance the sunscreen scattering effect of well-known ultraviolet (UV) blockers. One of the major challenges remains its penetration capacity into deeper skin layers, which may be achieved by the use of nanosized delivery systems, yet without the risk of transdermal delivery. In this review, we discuss the nutraceutical value of caffeine in cosmetic products, so-called nutricosmetics, which grants this bioactive several advantages in several formulations, in comparison to other potential bioactives of nutricosmetic value. Furthermore, the disclosed effects of bioactives commonly found in coffee, tea, and their by-products are reviewed and discussed. The discussion concludes by highlighting the significant benefits of caffeine in the treatment of skin disorders and its potential to enhance and promote skin health.

Genomic Markers and Personalized Medicine in Androgenetic Alopecia: A Comprehensive Review

Androgenetic alopecia (AGA) is the most common form of hair loss, significantly affecting both men and women worldwide. Characterized by progressive hair thinning and loss, AGA is primarily mediated by dihydrotestosterone (DHT). Recent research has identified numerous single-nucleotide polymorphisms (SNPs) associated with AGA, particularly in genes involved in androgen metabolism, prostaglandin pathways, and vasodilation. These genetic markers offer insights into AGA pathophysiology and potential therapeutic targets. Pharmacogenetics, the study of how genetic variations influence drug response, holds promise for personalized AGA treatment. Identifying SNPs that affect the efficacy of treatments like minoxidil and finasteride enables the development of tailored therapeutic strategies. For instance, genetic variants in the SRD5A2 gene, which affects DHT metabolism, can predict responsiveness to 5-alpha-reductase inhibitors. Beyond pharmacogenetics, RNA interference (RNAi) technologies, e.g., small interfering RNAs (siRNAs), present new therapeutic avenues. Studies have shown the efficacy of RNAi-based treatments in targeting androgen receptors, promoting hair growth in AGA models. Integrating genetic and pharmacogenetic research into clinical practice can transform AGA management, enhancing treatment efficacy and patient outcomes. In conclusion, genetic and pharmacogenetic insights are crucial for developing personalized treatments for AGA, while emerging RNAi technologies offer promising new interventions. These advancements represent significant steps toward more effective and individualized AGA therapies.

FORENSIC DNA PHENOTYPING FOR CRIMINAL IDENTIFICATION

The purpose of the work – to carry out an analysis of modern achievements andpossibilities of forensic DNA phenotyping to determine the external characteristics ofa person, his biogeographical origin and age in order to facilitate criminal investigations.Conclusions. Forensic DNA Phenotyping (FDP) involves the prediction of a person’sexternal characteristics regarding appearance, biogeographic origin, and age based onDNA samples from a crime scene to support investigations and help to find unknowncriminals who cannot be identified through forensic STR profiling.DNA-based appearance prediction has moved beyond eye, hair and skin color andincluded new features such as eyebrow color, freckles, hair structure, male pattern hairloss and height. DNA-based biogeographic inference of ancestry has progressed fromcontinental ancestry to detecting subcontinental ancestry and resolving models of commonancestry in genetically mixed individuals. DNA-based age estimation is now possible notonly through blood testing, but also through somatic tissues such as saliva and bone, aswell as new markers and tools for analyzing semen. Technological advances have madeit possible to use forensic DNA technology with greatly increased multiplexing capabilityto simultaneously analyze hundreds of DNA predictors using targeted massively parallelsequencing (MPS). Forensically validated MPS-based FDP tools for DNA-based crimescene prediction are used to identify: several features of appearance; multiregional origin;several appearance features together with multiregional origin; age by different tissue types. Despite recent advances that are likely to increase the impact of FDP in criminal casesin the near future, bringing reliable prediction of appearance, ancestry, and age fromcrime scene DNA to the level of detail and accuracy, that forensic scientists may desire,requires further intensive scientific research, along with technical developments andforensic validation.

Structural perspectives on the androgen receptor, the elusive shape-shifter

The androgen receptor (AR) is a type I nuclear receptor and master transcription factor responsible for development and maintenance of male secondary sex characteristics. Aberrant AR activity is associated with numerous diseases, including prostate cancer, androgen insensitivity syndrome, spinal and bulbar muscular atrophy, and androgenic alopecia. Recent studies have shown that AR adopts numerous conformations that can modulate its ability to bind and transcribe its target DNA substrates, a feature that can be hijacked in the context of cancer. Here, we summarize a series of structural observations describing how this elusive shape-shifter binds to multiple partners, including self-interactions, DNA, and steroid and non-steroidal ligands. We present evidence that AR’s pervasive structural plasticity confers an ability to broadly bind and transcribe numerous ligands in the normal and disease state, and explain the structural basis for adaptive resistance mutations to antiandrogen treatment. These evolutionary features are integral to receptor function, and are commonly lost in androgen insensitivity syndrome, or reinforced in cancer.

Minoxidil cyclodextrin complexes and their inclusion in transfersomes for the enhancement of therapeutic effect on androgenic alopecia

To further increase the drug loading (DL) of minoxidil (MXD) in transfersomes and fully utilize its role in the treatment of androgen alopecia (AGA), a strategy of drug in-cyclodextrin (CD)-in transfersomes was adopted and investigated. The sulfobutyl-substituted β-CDs (SBE-β-CD) with highest optimal binding energy was selected as the most suitable CD for MXD through molecular docking, which had high solubilization effect on MXD verified by phase solubility study. The transfersomes bearing inclusion complexes of MXD/SBE-β-CD was prepared by thin film hydration method, and the MXD/SBE-β-CD transfersomes (MXD/SCD@TFs) with the mass ratio of 10: 3: 2.5: 6 for phosphatidylcholine, cholesterol, Tween80 and MXD was selected as the optimal prescription through single factor screening, which had particle size of less than 100 nm, zeta potential of (−36.4 ± 0.11) mV. The DL of MXD/SCD@TFs was (44.02 ± 0.16)% (n = 3), which was increased nearly 3 times of MXD@TFs, resulting higher stability, in vitro skin permeation activity and drug skin retention. Importantly, the length of newborn hair and the length and number of hair follicles after 21 days of administration of MXD/SCD@TFs on AGA model C57BL/6 mice were significantly higher than those of MXD@TFs and commercial tincture (p < 0.01). Obviously, improving DL is an effective means to improve the therapeutic effect of MXD transfersoms on AGA, the screening of suitable CD for MXD and the loading of inclusion complex in transfersomes provide promising strategy to achieve it.

Effectiveness of Exosome Treatment in Androgenetic Alopecia: Outcomes of a Prospective Study.

Harnessing the regenerative capabilities of stem cell-derived exosomes holds great promise for developing novel hair growth therapies, offering hope for individuals experiencing hair loss or alopecia. This aimed to elucidate the effect of "foreskin-derived mesenchymal stromal cells derived exosome" injection into the scalp on hair density in patients with androgenetic alopecia and the contribution of this treatment on patient satisfaction. This prospective study included 30 male patients, aged between 22 and 65, with hair type III-VI according to the Norwood-Hamilton scale. Characterization of the stem cell exosomes was performed with the nanoparticle tracking analysis (NTA), hair densities were calculated via digital imaging analysis, and patient satisfaction was questioned with a modified survey. NTA results showed a characteristic distribution of peaks for exosomes 139.7 ± 2.3nm in diameter. A statistically significant increase in hair density was observed in the 4th and 12th weeks after treatment (p < 0.05). Patient-reported satisfaction revealed a statistically significant difference in the answers given in the 12th week compared to the 4th week (p < 0.05). No side effects or complications were observed after exosome injection. Foreskin-derived mesenchymal stromal cells derived exosome injection increased hair density, with sustained patient satisfaction throughout the study. The exosome application resulted in no side effects. This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

Evaluation of the safety and efficacy of concentrated growth factors for hair growth promotion in androgenetic alopecia patients: A retrospective single-centre, single-arm study.

This study was designed to evaluate the safety and efficacy of injections of concentrated growth factors (CGF) for hair growth promotion in androgenetic alopecia (AGA) patients. A retrospective review of AGA patients treated with injections of CGF at our center from October 2021 to April 2023 was performed. A total of 3 injections were administered every 3-4 weeks apart, and evaluation were performed before the first injection and at 3 months, 6 months later. The outcomes were assessed by trichoscopy photomicrographs and the Global Aesthetic Improvement Scale (GAIS). At 3 months after the first injection, the hair density and hair growth ratio were significantly improved. Significant improvements were found in GAIS score by both patients and independent doctors and the hair growth promotion was sustained for 6 months after first treatment. According to this tiny single-arm trial, the use of CGF injection may help AGA by increasing terminal hair density and hair density. No severe topical or systemic adverse events occurred during the treatment.

Clinical Experience of Professor Ma Shuanquan in Treating Androgenetic Alopecia

Clinical Experience of Professor Ma Shuanquan in Treating Androgenetic Alopecia